Related Experiment Videos
Long-term survival in refractory recurrent neuroblastoma
1Department of Internal Medicine, University of Kentucky Medical Center, Lucille Parker Markey Cancer Center, Lexington 40536-0093, USA.
Journal of Pediatric Hematology/Oncology
|May 1, 1996
Summary
Long-term survival is possible for patients with metastatic neuroblastoma (a rare childhood cancer) even with recurrent disease. This case highlights potential for improved outcomes in stage IV neuroblastoma without extralymphatic metastasis.
Area of Science:
- Pediatric Oncology
- Neuroblastoma Research
- Cancer Metastasis
Background:
- Metastatic neuroblastoma in patients over 1 year old typically has a poor prognosis.
- This study presents a unique case of a patient with disseminated nodal disease and multiple relapses, achieving a 14-year survival.
- The case challenges conventional survival expectations for advanced neuroblastoma.
Observation:
- A literature review identified 11 additional patients with stage IV neuroblastoma without extralymphatic metastasis.
- The presented case and literature review focus on patients with advanced disease but no hematogenous spread.
- Favorable prognostic factors, including histology and N-myc oncogene copy number, were noted in the case.
Findings:
- Patients with stage IV neuroblastoma without extralymphatic metastasis show a trend toward improved survival (50% at 5 years vs. 15% in historical controls).
- Long-term survival with recurrent disease, as seen in this case, is a novel observation in this patient population.
- The current case exhibited favorable histology and a single N-myc oncogene copy.
Implications:
- Nonhematogeneous stage IV neuroblastoma may have a better survival rate than previously thought.
- Further prospective studies are needed to confirm the potential for long-term survival in patients with residual disease and without extralymphatic metastasis.
- This research may inform future treatment strategies for advanced neuroblastoma.